Sai Parenteral's
SAIPARENTNSE

Sai Parenteral's

₹588.10-8.00 (1.34%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
579.50
Today’s high
608.30
52 week low
400.00
52 week high
706.00
Open price
596.10
Previous close
596.10
Live volume
3,04,478
Lower circuit
470.50
Upper circuit
705.70

Fundamentals

Market Cap
₹2,632Cr
ROE
2.91%
P/E Ratio(TTM)
184.44
EPS(TTM)
3.23
P/B Ratio
5.36
Dividend Yield
0.00%
Industry P/E
35.68
Book Value
111.09
Debt to Equity
0.68
Face Value
5

Financial performance

Quarterly
Yearly
All Financials
MAR '26
Revenue (Cr)
₹201
+102.27%
Profit (Cr)
₹13.16
+297.60%
-75075150225
Dec '25
Mar '26

About

Sai Parenterals is a diversified pharmaceutical formulations company. While it started as a specialist in "parenterals" (injectables), it has evolved into a multi-dosage platform. Its business is split into two main verticals:Branded Generic Formulations and CDMO (Contract Development and Manufacturing). The company covers high-growth therapeutic areas such as cardiovascular, anti-diabetic, neuropsychiatry, and oncology. It operates five manufacturing facilities—four in Hyderabad (Telangana) and one in Ongole (Andhra Pradesh).;
CEO/MD
Anil Kumar Karusala
Founded in
2001
NSE symbol
SAIPARENT

Shareholding Pattern

Apr '26
Mar '26
Sep '25
Promoters
61.23%
Retail And Others
38.77%
Livesquawk
Sai Parenterals schedules analyst and investor meeting on July 2. The meeting will focus on company updates and future outlook.
Livesquawk
Sai Parenterals plans FY27 capex: ₹118 Cr for India expansion, EU-GMP upgrades. AUD 53 Mn for Australia's largest pharma plant, ₹18 Cr for R&D center.
Livesquawk
Sai Parenterals targets Rs 750 crore revenue for FY27, per MD. The company aims to achieve EBITDA margin expansion up to 17%.
2026
23
May
Quarterly & Annual Result
Release date
Events calendar
View upcoming events in other stocks